NCT02704728View on ClinicalTrials.gov

Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Crohn's Disease
Interventions
OTHER

Thetanix

Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.

OTHER

Placebo

Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.

Trial Locations (5)

B46NH

Birmingham Children's Hospital, Birmingham

EH6 1LF

Clinical Research Facility, Edinburgh

G514TF

Clinical Research Faciity, Glasgow

L12 2AP

Alder Hey Children's Hospital, Liverpool

E1 1BB

Barts Health NHS Trust, London

All Listed Sponsors
lead

4D pharma plc

INDUSTRY

NCT02704728 - Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease | Biotech Hunter | Biotech Hunter